

### **AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-39 (canceled).

40. (New) A method of immunizing a host comprising introducing into the host a therapeutic amount of a peptide antigen of virus MvP-5180/91, deposited with the European Collection of Animal Cell Culture (ECACC).

41. (New) A method of immunizing a non-human host comprising introducing into the host a therapeutic amount of virus MvP-5180/91, deposited with the European Collection of Animal Cell Culture (ECACC).

42. (New) A method of immunizing a host comprising introducing into the host a therapeutic amount of a peptide antigen of a variant virus, wherein the variant virus is a variant of virus MvP-5180/91, deposited with the European Collection of Animal Cell Culture (ECACC).

43. (New) A method of immunizing a non-human host comprising introducing into the host a therapeutic amount of a variant virus, wherein the variant virus is a variant of virus MvP-5180/91, deposited with the European Collection of Animal Cell Culture (ECACC).

44. (New) A method for detection of antibodies that specifically bind to at least one HIV retrovirus, said method comprising:

- (a) providing a sample containing at least one antibody obtained from a patient suspected of being infected with an HIV virus;

- (b) providing at least one peptide comprising an amino acid sequence encoded by the genome of virus MvP-5180/91 (SEQ ID NO: 56);
- (c) combining the sample and the at least one peptide under conditions where the at least one peptide and the at least one antibody can specifically bind to each other;
- (d) determining whether the at least one peptide and the at least one antibody specifically bound to each other; and
- (e) optionally, quantifying the amount of binding between the at least one peptide and the at least one antibody,

wherein the method is a Western blot.